Literature DB >> 27283868

Stability of clinical outcome measures in rheumatoid arthritis patients with stable disease defined on the basis of the EULAR response criteria.

Ole Rintek Madsen1,2.   

Abstract

Natural variation also known as measurement error is assessed in individuals in "steady state." The study aimed to examine inter-visit variations in clinical outcome measures in rheumatoid arthritis (RA) patients with stable disease defined on the basis of the EULAR response criteria. Two hundred thirty-three RA patients with stable disease defined as a change in Disease Activity Score (DAS28-CRP) ≤0.6 between two consecutive visits were identified in the Danish rheumatology registry for biological treatment (DANBIO). Clinical data from a single set of such two visits were extracted for each patient. Using the Bland-Altman method, lower and upper 95 % limits of agreement (LLoA; ULoA) between the consecutive assessments and the bias were calculated for each measure. Associations were characterized by Pearson's r-values and standard errors of estimation (SEE). The mean change in DAS28-CRP was 0.0 ± 0.3. Agreements between the assessments were close on the group level but poor on the individual level. For example, LLoA; ULoA [bias] for patient global assessment (0-100) was -28.3; 29.7 [0.7], for fatigue (0-100) -38.1; 36.3 [-0.9] and for 28 swollen joint count -3.3; 3.3 [0.0]. Inter-visit differences were poorly explained by the baseline values (r [SEE] ranging from 0.15 [12.6] for fatigue to 0.58 [1.4] for 28 tender joint count) and by changes in other outcome variables. In conclusion, outcome measures fluctuated substantially and unpredictably in individual RA patients considered in steady state. The observed between-visit differences may be interpreted to reflect natural variation or measurement error that should be taken into account when monitoring patients in the daily clinic.

Entities:  

Keywords:  DAS28-CRP; Natural variation; Outcome measure; Response criteria; Rheumatoid arthritis

Mesh:

Substances:

Year:  2016        PMID: 27283868     DOI: 10.1007/s10067-016-3322-x

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  41 in total

1.  Coping Styles, Pain Expressiveness, and Implicit Theories of Chronic Pain.

Authors:  N C Higgins; S Jeffrey Bailey; Diane L LaChapelle; Katherine Harman; Thomas Hadjistavropoulos
Journal:  J Psychol       Date:  2014-11-14

2.  Improved monitoring of differences in serial laboratory results.

Authors:  Callum G Fraser
Journal:  Clin Chem       Date:  2011-10-05       Impact factor: 8.327

3.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

4.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Authors:  M L Prevoo; M A van 't Hof; H H Kuper; M A van Leeuwen; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1995-01

5.  Test-retest reliability of disease activity core set measures and indices in rheumatoid arthritis.

Authors:  T Uhlig; T K Kvien; T Pincus
Journal:  Ann Rheum Dis       Date:  2008-10-28       Impact factor: 19.103

6.  Fatigue in rheumatoid arthritis: the role of self-efficacy and problematic social support.

Authors:  R P Riemsma; J J Rasker; E Taal; E N Griep; J M Wouters; O Wiegman
Journal:  Br J Rheumatol       Date:  1998-10

7.  Predictors of subjective fatigue among individuals with rheumatoid arthritis.

Authors:  B A Huyser; J C Parker; R Thoreson; K L Smarr; J C Johnson; R Hoffman
Journal:  Arthritis Rheum       Date:  1998-12

8.  Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials.

Authors:  Theodore Pincus; Ingrid Amara; Oscar G Segurado; Martin Bergman; Gary G Koch
Journal:  J Rheumatol       Date:  2007-11-15       Impact factor: 4.666

9.  Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.

Authors:  Merete Lund Hetland; Ib Jarle Christensen; Ulrik Tarp; Lene Dreyer; Annette Hansen; Ib Tønder Hansen; Gina Kollerup; Louise Linde; Hanne M Lindegaard; Uta Engling Poulsen; Annette Schlemmer; Dorte Vendelbo Jensen; Signe Jensen; Gisela Hostenkamp; Mikkel Østergaard
Journal:  Arthritis Rheum       Date:  2010-01

10.  What are the essential elements to enable patient participation in medical decision making?

Authors:  Liana Fraenkel; Sarah McGraw
Journal:  J Gen Intern Med       Date:  2007-05       Impact factor: 5.128

View more
  1 in total

1.  Exploring the Inflammatory Metabolomic Profile to Predict Response to TNF-α Inhibitors in Rheumatoid Arthritis.

Authors:  Bart V J Cuppen; Junzeng Fu; Herman A van Wietmarschen; Amy C Harms; Slavik Koval; Anne C A Marijnissen; Judith J W Peeters; Johannes W J Bijlsma; Janneke Tekstra; Jacob M van Laar; Thomas Hankemeier; Floris P J G Lafeber; Jan van der Greef
Journal:  PLoS One       Date:  2016-09-15       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.